Shire Korea, the local branch of the global biotech pharmaceutical Shire, held a symposium on Monday celebrating the launch of Adynovate, its long-lasting factor VIII gene recombinant hemophilia A treatment.
Supplemental BLA based on clinical trial results from the Phase 3 TEN02 Study, a prospective study of Coagadex® for prophylaxis of bleeding episodes in children under 12 years old with moderate to severe hereditary factor X deficiency